BioStock: PHI “It’s the right moment to capitalize on regenerative medicine momentum.”

Medtech company Phase Holographic Imaging recently secured a loan facility of SEK 7 million. The company has decided to draw the first tranche from that loan — SEK 4.5 million. In a press release, CEO Patrik Eschricht stated that this provides an opportunity to act on the company’s current momentum. BioStock talked to Eschricht to learn more.

Read the full interview with Patrik Eschricht on

This strategic loan enables us to better lay the groundwork for entering the clinical market. We can leverage the current momentum and accelerate our development projects and product-to-market timeline.

Further reading

PHI published a detailed perspective discussing the versatility and potential the Company sees for Quantitative Phase Imaging (QPI) technology in Regenerative Medicine. PHI outlines how QPI will offer enhanced cell quality control in the cell manufacturing process, thereby addressing a central puzzle piece for making cell-based therapies safe, affordable, and accessible for all.